BMYMP
Price:
$878
Market Cap:
$105.76B
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Industry
Drug Manufacturers - General
IPO Date
2003-12-08
Stock Exchange
OTC
Ticker
BMYMP
According to Bristol-Myers Squibb Company PFD CONV 2’s latest financial reports and current stock price. The company's current ROE is 34.65%. This represents a change of 308.36% compared to the average of 8.49% of the last 4 quarters.
The mean historical ROE of Bristol-Myers Squibb Company PFD CONV 2 over the last ten years is 7.74%. The current 34.65% ROE has changed 347.91% with respect to the historical average. Over the past ten years (40 quarters), BMYMP's ROE was at its highest in in the March 2025 quarter at 14.12%. The ROE was at its lowest in in the March 2024 quarter at -72.23%.
Average
7.74%
Median
15.21%
Minimum
-54.78%
Maximum
35.07%
Discovering the peaks and valleys of Bristol-Myers Squibb Company PFD CONV 2 ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 308.84%
Maximum Annual ROE = 35.07%
Minimum Annual Increase = -456.83%
Minimum Annual ROE = -54.78%
| Year | ROE | Change |
|---|---|---|
| 2024 | -54.78% | -300.89% |
| 2023 | 27.27% | 33.87% |
| 2022 | 20.37% | 4.69% |
| 2021 | 19.46% | -181.81% |
| 2020 | -23.78% | -456.83% |
| 2019 | 6.66% | -80.99% |
| 2018 | 35.07% | 308.84% |
| 2017 | 8.58% | -68.87% |
| 2016 | 27.55% | 151.15% |
| 2015 | 10.97% | -18.70% |
The current ROE of Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.38%
5-year avg
-2.29%
10-year avg
7.74%
Bristol-Myers Squibb Company PFD CONV 2’s ROE is less than Roche Holding AG (18.94%), less than Roche Holding AG (18.94%), less than Roche Holding AG (18.94%), less than AstraZeneca PLC (20.20%), less than Novartis AG (34.12%), less than Sanofi (12.39%), less than GSK plc (37.40%), less than Chugai Pharmaceutical Co., Ltd. (20.83%), less than Chugai Pharmaceutical Co., Ltd. (20.83%), greater than Bayer AG (-10.91%),
| Company | ROE | Market cap |
|---|---|---|
| 18.94% | $314.77B | |
| 18.94% | $322.26B | |
| 18.94% | $307.13B | |
| 20.20% | $284.14B | |
| 34.12% | $242.96B | |
| 12.39% | $119.32B | |
| 37.40% | $98.09B | |
| 20.83% | $89.07B | |
| 20.83% | $91.19B | |
| -10.91% | $38.39B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bristol-Myers Squibb Company PFD CONV 2 using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Bristol-Myers Squibb Company PFD CONV 2 or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Bristol-Myers Squibb Company PFD CONV 2's ROE?
How is the ROE calculated for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)?
What is the highest ROE for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)?
What is the 3-year average ROE for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)?
What is the 5-year average ROE for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP)?
How does the current ROE for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) compare to its historical average?